HY008

HY008 is an experimental combination therapy being developed by Helperby Therapeutics to treat antimicrobial-resistant (AMR) bacterial infections. The therapy is part of Helperby's "Antibiotic Resistance Breaker" (ARB) platform, which pairs existing antibiotics with non-antibiotic compounds to restore their efficacy against resistant strains. Specifically, HY008 is a tetracycline-based combination therapy, meaning it utilizes an antibiotic from the tetracycline class alongside a resistance-breaking agent. This approach is designed to overcome bacterial resistance mechanisms that would otherwise render tetracyclines ineffective, thereby extending the clinical utility of this antibiotic class against multi-drug resistant pathogens.